60 DEGREES PHARMACEUTICALS, INC.SXTPEarnings & Financial Report
Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
SXTP Q4 FY2025 Key Financial Metrics
Revenue
$303.4K
Gross Profit
$182.7K
Operating Profit
$-1.9M
Net Profit
$-1.4M
Gross Margin
60.2%
Operating Margin
-632.0%
Net Margin
-474.2%
YoY Growth
25.6%
EPS
$-8.26
60 DEGREES PHARMACEUTICALS, INC. Q4 FY2025 Financial Summary
60 DEGREES PHARMACEUTICALS, INC. reported revenue of $303.4K (up 25.6% YoY) for Q4 FY2025, with a net profit of $-1.4M (up 29.7% YoY) (-474.2% margin). Cost of goods sold was $120.7K, operating expenses totaled $2.1M.
Key Financial Metrics
| Total Revenue | $303.4K |
|---|---|
| Net Profit | $-1.4M |
| Gross Margin | 60.2% |
| Operating Margin | -632.0% |
| Report Period | Q4 FY2025 |
60 DEGREES PHARMACEUTICALS, INC. Annual Revenue by Year
60 DEGREES PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.0M).
60 DEGREES PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
60 DEGREES PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $303.4K | +25.6% | $-1.4M | -474.2% |
| Q3 FY2025 | $437.6K | +223.4% | $-2.3M | -529.3% |
| Q2 FY2025 | $100.9K | -19.2% | $-1.7M | -1717.7% |
| Q1 FY2025 | $163.6K | +54.8% | $-1.9M | -1147.4% |
| Q4 FY2024 | $241.6K | — | $-2.0M | -846.3% |
| Q3 FY2024 | $135.3K | +164.3% | $-2.2M | -1596.4% |
| Q2 FY2024 | $125.0K | +109.9% | $-4.2M | -3339.0% |
| Q1 FY2024 | $105.7K | — | $430.5K | 407.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105674 | $124972 | $135293 | $241635 | $163552 | $100932 | $437602 | $303385 |
| YoY Growth | N/A | 109.9% | 164.3% | N/A | 54.8% | -19.2% | 223.4% | 25.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $8.4M | $4.3M | $7.4M | $5.8M | $6.0M | $4.2M | $6.7M | $5.4M |
| Liabilities | $1.3M | $1.4M | $1.5M | $1.8M | $1.9M | $1.8M | $2.3M | $2.0M |
| Equity | $7.2M | $3.0M | $6.0M | $4.0M | $4.1M | $2.4M | $4.4M | $3.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.1M | $-1.2M | $-1.7M | $-1.6M | $-1.6M | $-1.5M | $-2.1M | $-1.7M |